SAB Biotherapeutics (SABS) Expected to Post Quarterly Earnings on Thursday

SAB Biotherapeutics (NASDAQ:SABS) is anticipated to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.27) per share and revenue of $0.12 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.28) EPS for the quarter, meeting the consensus estimate of ($0.28). On average, analysts expect SAB Biotherapeutics to post ($1.17) EPS for the current fiscal year and ($0.79) EPS for the next fiscal year.

SAB Biotherapeutics Stock Performance

Shares of SABS traded down $0.15 during trading hours on Tuesday, hitting $3.15. The company had a trading volume of 136,142 shares, compared to its average volume of 638,961. The business has a fifty day moving average of $3.25 and a 200-day moving average of $3.68. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.01. The firm has a market cap of $286.61 million, a price-to-earnings ratio of -2.42 and a beta of 0.58. SAB Biotherapeutics has a 12 month low of $2.44 and a 12 month high of $5.15.

Wall Street Analyst Weigh In

A number of brokerages recently commented on SABS. Weiss Ratings upgraded shares of SAB Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th. Wall Street Zen upgraded shares of SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, August 10th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a biotechnology company focused on developing fully human polyclonal antibody medicines for infectious diseases, immune disorders and other conditions where targeted immune responses may provide therapeutic benefits. The company is based in Sioux Falls, South Dakota.

SAB Biotherapeutics uses its DiversitAb platform, which involves genetically engineered cattle capable of producing antibodies with human immune-system characteristics. Antibodies are collected from the animals’ plasma and processed for potential use as treatments, allowing the company to pursue antibody products without relying solely on conventional human donor sources.

The company has developed a pipeline that has included SAB-185, an investigational antibody therapy directed at SARS-CoV-2, as well as programs targeting influenza and autoimmune or immune-mediated diseases.